NCT06116565View on ClinicalTrials.gov

A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

March 30, 2024

Primary Completion Date

March 30, 2026

Study Completion Date

March 30, 2026

Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL

CM310

CM310, subcutaneous injection

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT06116565 - A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter